S
Sano Genetics
Building the future of precision medicine with genomics
About Sano Genetics
Sano Genetics operates in the precision medicine research industry, providing a comprehensive platform that integrates genetic testing, participant recruitment, and long-term engagement to accelerate clinical trials. The company serves pharmaceutical companies, biotech firms, and academic researchers who are conducting personalized medicine studies. Sano's platform simplifies the complex process of DNA testing studies, making it more efficient and cost-effective. The business model is based on offering a tech-forward, user-friendly solution that de-risks trials, enabling clinical operations teams to move 10 times faster and reduce costs by 5 times. Revenue is generated through subscription fees and service charges for the use of their platform and additional support services. Sano's approach is human-centric, focusing on making research engaging, transparent, and meaningful for participants. The company also offers electronic medical record retrieval, providing up to seven years of curated medical history to support research efforts.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Cambridge, United Kingdom
- Employees
- 51
- Open positions
- None listed
- Dealroom signal
- 61.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Precision Medicine, Spinout, Genome Engineering, Biotech and Pharma, AI Drug Discovery
- Technology
- Big Data
- Business model
- Marketplace & ecommerce
- Client focus
- b2b, b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Other✓Other financing | Jul 2024 | $0 | — | PharmStars | ↗ |
| EARLY VC✓Equity / VC | Jan 2024 | $12M | $47M | Plural | ↗ |
Growth signals
Latest recorded traffic for Sano Genetics is 13K monthly website visits, down 7.1% over the last three months. Sano Genetics's team declined 42.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Cambridge University Entrepreneurs
Seedcamp
Paul Forster
Cambridge Enterprise
Will Neale
University of Cambridge
Series A10 investors entered at this stage
January Ventures
Episode 1 Ventures
MMC Ventures
Gousto
Signal AI
Current Health- MGMargo Georgiadis
PatientsLikeMe
Paul Wicks
Plural
Other known investors8 additional known investors
Google for Startups Accelerator
KQ Labs
PharmStars
Cambridge Angels
Deepali Nangia
Parkwalk Advisors
Synetro Group
University of Bristol Enterprise Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sano Genetics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sano Genetics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.